CTOs on the Move

Citra-Solv

www.citrasolv.com

 
Citra-Solv LLC is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Nerium International

At Nerium International, making people better means establishing a business that can bring real change to your life, your skin, and your personal development.   Through our partnership with Nerium SkinCare, a division of Nerium Biotechnology, Inc., Nerium International markets breakthrough products validated by real science.   These age-defying skincare products are distributed exclusively by our Independent Brand Partners.

Mirati

Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet medical need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati`s vision is to unlock the science behind the promise of a life beyond cancer.

Apollomics

At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.

Selexys Pharmaceuticals

Selexys Pharmaceuticals is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Century Therapeutics

Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.